EGM
GYRE icon

Engineers Gate Manager’s Gyre Therapeutics GYRE Stock Holding History

Engineers Gate Manager’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,143
Closed -$15K – 2029
2021
Q4 		$15K Buy
+2,143
New +$36.6K ﹤0.01% 1950
2021
Q2 		– Sell
-2,413
Closed -$91K – 1763
2021
Q1 		$91K Buy
2,413
+626
+35% +$28.6K ﹤0.01% 1716
2020
Q4 		$85K Buy
1,787
+120
+7% +$5.2K ﹤0.01% 1602
2020
Q3 		$54K Sell
1,667
-906
-35% -$35.5K ﹤0.01% 1603
2020
Q2 		$113K Buy
2,573
+853
+50% +$40.1K 0.01% 1566
2020
Q1 		$56K Buy
+1,720
New +$79K ﹤0.01% 1476

Other funds holding GYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

Engineers Gate Manager's GYRE Position: Q1 2022 in Review

Engineers Gate Manager sold out of Gyre Therapeutics (GYRE) in Q1 2022, closing a stake of 2,143 shares — an estimated $15K sold.

Engineers Gate Manager first reported a position in GYRE in Q1 2020 and held it in 6 quarters. The position peaked at $113K in Q2 2020. 43 funds tracked by Wall St. Rank hold GYRE as of Q1 2022.

  • Engineers Gate Manager reported no remaining Gyre Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Engineers Gate Manager sold 2,143 Gyre Therapeutics shares in Q1 2022, an estimated $15K.
  • Engineers Gate Manager first reported a position in Gyre Therapeutics in Q1 2020 and held it in 6 quarters.
  • Engineers Gate Manager's Gyre Therapeutics position peaked at $113K in Q2 2020.
  • 43 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q1 2022.

Based on Engineers Gate Manager's 13F filing for Q1 2022, filed 16 May 2022.